Results 121 to 130 of about 381,559 (266)

Socioeconomic Status and Access to Treatment in Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Joonas K, Katja M, Susanna T, Marjukka P, Sirkku J, Minna S, Anu P, Kristiina V, Kaisa S, Aino R, Annikki AH, Tuula K, Anna H, Milla ELK, Hanne K, Outi K.   +15 more
europepmc   +1 more source

A C‐Nucleoside Analogue of Cordycepin With High Metabolic Stability and Potent Anti‐Psoriatic Activity via Microneedle Delivery

Advanced Science, EarlyView.
This work identified CPD3a as a potent, stable C‐nucleoside cordycepin derivative. When formulated into microneedle array for topical treatment, it ameliorated psoriasis by rebalancing immunity and enhancing antioxidant defenses. ABSTRACT Psoriasis is a chronic inflammatory disorder characterized by immune dysregulation and epidermal hyperplasia ...
Wenfang Pan, Xinyue Shao, Yuanchen Zhong, Xujie Sun, Lixuan Yin, Zongyan He, Tianqun Lang, Yuanchao Xie   +7 more
wiley   +1 more source

Diffuse Large B-Cell Lymphoma Presenting in a Background of Rosai-Dorfman Disease. [PDF]

Case Rep Hematol
Wu C, Meyer A, Tun AM.
europepmc   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

Annals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki   +9 more
wiley   +1 more source

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Spriano F, Cascione L, Tarantelli C, Sartori G, Arribas AJ, Velasova A, Napoli S, Havranek O, Toretsky JA, Bertoni F.   +9 more
europepmc   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT‐SAAWP RACE Study

American Journal of Hematology, EarlyView.
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano, Simona Iacobelli, Austin Kulasekararaj, Marleen van Os, Sofie R. Terwel, Joe Tuffnell, Brian Piepenbroek, Morag Griffin, Constantijn J. M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Juan Carlos Vallejo, Beatrice Drexler, Jean‐Baptiste Mear, Roochi Trikha, Shreyans Gandhi, Anna Maria Raiola, L. G. M. Daenen, Marco R. de Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda, Isabel Sánchez‐Ortega, Blanca Xicoy, Isidro Jarque, James Cavenagh, Flore Sicre de Fontbrune, Camilla Frieri, Talha Munir, Jennifer M. L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob R. Passweg, Gérard Socié, Ghulam J. Mufti, Carlo Dufour, Régis Peffault de Latour, Severe Aplastic Anaemia Working Party of the EBMT   +52 more
wiley   +1 more source

Metabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma. [PDF]

Oncogenesis
Neumann MA, Frezza C.
europepmc   +1 more source

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir, Ahmed Sayed, Dae Hyun Lee, Sanam Ghazi, Mustafa M. Houmsse, Saad Badat, Abdul Moeed, Avirup Guha, Daniel Addison, Narendranath Epperla   +9 more
wiley   +1 more source

PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis. [PDF]

Leukemia
Liu Y, Chen R, Gao X, Zhu F, Ni Q, Bates PD, Wu S, Zai Z, Obernberger VA, Weerawardhene K, Tourdot TK, Petta S, Conyers MJ, Capitini CM, Rui L.   +14 more
europepmc   +1 more source